Migrating to Long-Read Sequencing for Clinical Routine TKI Resistance Mutation Screening

Objective: The aim of this project was to implement long-read sequencing for BCR-ABL1 TKI resistance mutation screening in a clinical setting for patients undergoing treatment for chronic myeloid leukemia. Materials and Methods: Processes were established for registering and transferring samples fro...

Full description

Bibliographic Details
Main Authors: Wesley Schaal, Adam Ameur, Ulla Olsson-Strömberg, Monica Hermanson, Lucia Cavelier, Ola Spjuth
Format: Article
Language:English
Published: SAGE Publishing 2022-07-01
Series:Cancer Informatics
Online Access:https://doi.org/10.1177/11769351221110872
_version_ 1818197583912239104
author Wesley Schaal
Adam Ameur
Ulla Olsson-Strömberg
Monica Hermanson
Lucia Cavelier
Ola Spjuth
author_facet Wesley Schaal
Adam Ameur
Ulla Olsson-Strömberg
Monica Hermanson
Lucia Cavelier
Ola Spjuth
author_sort Wesley Schaal
collection DOAJ
description Objective: The aim of this project was to implement long-read sequencing for BCR-ABL1 TKI resistance mutation screening in a clinical setting for patients undergoing treatment for chronic myeloid leukemia. Materials and Methods: Processes were established for registering and transferring samples from the clinic to an academic sequencing facility for long-read sequencing. An automated analysis pipeline for detecting mutations was established, and an information system was implemented comprising features for data management, analysis and visualization. Clinical validation was performed by identifying BCR-ABL1 TKI resistance mutations by Sanger and long-read sequencing in parallel. The developed software is available as open source via GitHub at https://github.com/pharmbio/clamp Results: The information system enabled traceable transfer of samples from the clinic to the sequencing facility, robust and automated analysis of the long-read sequence data, and communication of results from sequence analysis in a reporting format that could be easily interpreted and acted upon by clinical experts. In a validation study, all 17 resistance mutations found by Sanger sequencing were also detected by long-read sequencing. An additional 16 mutations were found only by long-read sequencing, all of them with frequencies below the limit of detection for Sanger sequencing. The clonal distributions of co-existing mutations were automatically resolved through the long-read data analysis. After the implementation and validation, the clinical laboratory switched their routine protocol from using Sanger to long-read sequencing for this application. Conclusions: Long-read sequencing delivers results with higher sensitivity compared to Sanger sequencing and enables earlier detection of emerging TKI resistance mutations. The developed processes, analysis workflow, and software components lower barriers for adoption and could be extended to other applications.
first_indexed 2024-12-12T01:52:17Z
format Article
id doaj.art-4534f517db04444a98665e00a96b28af
institution Directory Open Access Journal
issn 1176-9351
language English
last_indexed 2024-12-12T01:52:17Z
publishDate 2022-07-01
publisher SAGE Publishing
record_format Article
series Cancer Informatics
spelling doaj.art-4534f517db04444a98665e00a96b28af2022-12-22T00:42:27ZengSAGE PublishingCancer Informatics1176-93512022-07-012110.1177/11769351221110872Migrating to Long-Read Sequencing for Clinical Routine TKI Resistance Mutation ScreeningWesley Schaal0Adam Ameur1Ulla Olsson-Strömberg2Monica Hermanson3Lucia Cavelier4Ola Spjuth5Pincer Bio AB, Uppsala, SwedenDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SwedenDepartment of Medical Sciences, Uppsala University Hospital, Uppsala, SwedenDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SwedenDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SwedenPincer Bio AB, Uppsala, SwedenObjective: The aim of this project was to implement long-read sequencing for BCR-ABL1 TKI resistance mutation screening in a clinical setting for patients undergoing treatment for chronic myeloid leukemia. Materials and Methods: Processes were established for registering and transferring samples from the clinic to an academic sequencing facility for long-read sequencing. An automated analysis pipeline for detecting mutations was established, and an information system was implemented comprising features for data management, analysis and visualization. Clinical validation was performed by identifying BCR-ABL1 TKI resistance mutations by Sanger and long-read sequencing in parallel. The developed software is available as open source via GitHub at https://github.com/pharmbio/clamp Results: The information system enabled traceable transfer of samples from the clinic to the sequencing facility, robust and automated analysis of the long-read sequence data, and communication of results from sequence analysis in a reporting format that could be easily interpreted and acted upon by clinical experts. In a validation study, all 17 resistance mutations found by Sanger sequencing were also detected by long-read sequencing. An additional 16 mutations were found only by long-read sequencing, all of them with frequencies below the limit of detection for Sanger sequencing. The clonal distributions of co-existing mutations were automatically resolved through the long-read data analysis. After the implementation and validation, the clinical laboratory switched their routine protocol from using Sanger to long-read sequencing for this application. Conclusions: Long-read sequencing delivers results with higher sensitivity compared to Sanger sequencing and enables earlier detection of emerging TKI resistance mutations. The developed processes, analysis workflow, and software components lower barriers for adoption and could be extended to other applications.https://doi.org/10.1177/11769351221110872
spellingShingle Wesley Schaal
Adam Ameur
Ulla Olsson-Strömberg
Monica Hermanson
Lucia Cavelier
Ola Spjuth
Migrating to Long-Read Sequencing for Clinical Routine TKI Resistance Mutation Screening
Cancer Informatics
title Migrating to Long-Read Sequencing for Clinical Routine TKI Resistance Mutation Screening
title_full Migrating to Long-Read Sequencing for Clinical Routine TKI Resistance Mutation Screening
title_fullStr Migrating to Long-Read Sequencing for Clinical Routine TKI Resistance Mutation Screening
title_full_unstemmed Migrating to Long-Read Sequencing for Clinical Routine TKI Resistance Mutation Screening
title_short Migrating to Long-Read Sequencing for Clinical Routine TKI Resistance Mutation Screening
title_sort migrating to long read sequencing for clinical routine tki resistance mutation screening
url https://doi.org/10.1177/11769351221110872
work_keys_str_mv AT wesleyschaal migratingtolongreadsequencingforclinicalroutinetkiresistancemutationscreening
AT adamameur migratingtolongreadsequencingforclinicalroutinetkiresistancemutationscreening
AT ullaolssonstromberg migratingtolongreadsequencingforclinicalroutinetkiresistancemutationscreening
AT monicahermanson migratingtolongreadsequencingforclinicalroutinetkiresistancemutationscreening
AT luciacavelier migratingtolongreadsequencingforclinicalroutinetkiresistancemutationscreening
AT olaspjuth migratingtolongreadsequencingforclinicalroutinetkiresistancemutationscreening